BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, announced the successful acquisition of Bi...
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...
In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...
As mRNA technologies move rapidly beyond COVID-19 into vaccines and therapies for cancer, rare diseases, and personalized medicine, scientific complexity i...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced a collaboration with the Stanford Center for Definitive and C...
Preliminary results for 2025: Group sales revenue rises by 7.6 percent to around 3.5 billion euros Positive development in both divi...
Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it ha...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...
- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases ...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and ful...
Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...
Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive the...
© 2026 Biopharma Boardroom. All Rights Reserved.
